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Abstract 
 
Single nucleotide variants (SNVs) within and surrounding the complement receptor 1 (CR1) gene show 
some of the strongest genome-wide association signals with late-onset Alzheimer’s disease. Some 
studies have suggested that this association signal is due to a duplication allele (CR1-B) of a low copy 
repeat (LCR) within the CR1 gene, which increases the number of complement C3b/C4b-binding sites in 
the mature receptor. In this study, we develop a triplex paralogue ratio test (PRT) assay for CR1 LCR copy 
number allowing large numbers of samples to be typed with a limited amount of DNA. We also develop 
a CR1-B allele-specific PCR based on the junction generated by an historical non-allelic homologous 
recombination event between CR1 LCRs. We use these methods to genotype CR1 and measure CR1-B 
allele frequency in both late-onset and early-onset cases and unaffected controls from the United 
Kingdom. Our data support an association of late-onset Alzheimer’s disease with the CR1-B allele, and 
confirm that this allele occurs most frequently on the risk haplotype defined by SNV alleles. 
Furthermore, regression models incorporating CR1-B genotype provide a bitter fit to our data compared 
to incorporating the SNP-defined risk haplotype, supporting the CR1-B allele as the variant underlying 
the increased risk of late-onset Alzheimer’s disease. 
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Introduction 
 
Alzheimer’s disease (AD) is a common neurodegenerative disease with an increasing disease burden in 
an aging population (Ballard et al. 2011). Familial early-onset AD can be caused by autosomal dominant 
variants in, for example, the amyloid precursor protein gene APP, the presenilin 1 gene PSEN1, and the 
presenilin 2 gene PSEN1 (Campion et al. 1999). Sporadic early onset AD (EOAD), with an age-of-onset of 
65 years or less, is defined as disease in the absence of these classical familial early-onset AD mutations. 
However, 99% of AD cases are late-onset AD (LOAD), which is a complex disease with multiple 
environmental and genetic contributions to its etiology. The most important genetic variant affecting 
LOAD risk is the APOE*E4 allele, which is a haplotype formed by rs429358-C and rs7412-C, generating a 
protein called APOE4 carrying arginine residues at position 130 and position 176 (Corder et al. 1998; 
Corder et al. 1993). This variant is associated with a 2-3-fold increase in LOAD risk for carriers, and a 15-
fold increase in risk for individuals homozygous for this variant (Farrer et al. 1997).  Genome-wide 
association studies (GWAS) on large cohorts have robustly identified 23 other variants with smaller 
effect sizes (Lambert et al. 2013; Lambert et al. 2009). Many of the genetic associations are with variants 
that lie within or near genes involved in the immune response. This has highlighted the importance of 
the immune response to amyloid plaque formation in Alzheimer’s disease, possibly mediated by 
microglial cells (Efthymiou and Goate 2017; Naj and Schellenberg 2017; Villegas-Llerena et al. 2016). 
 
One of the genes implicated in LOAD risk by GWAS is the complement C3b/C4b receptor 1 gene CR1. 
The receptor encoded by this gene is expressed on the surface of leukocytes and erythrocytes, and binds 
the C3b fragment of complement C3, and the C4b fragment of complement C4, as well as complement 
C1q. These interactions are important in the clearance of antibody-antigen immune complexes from the 
blood circulation, and in the phagocytosis of complement-tagged pathogens. Complement receptor 1 is 
also involved in the inflammatory response to injured tissue (Holers 2014) . 
 
Alleles at several SNVs both proximal, distal and within the CR1 gene have been identified as associated 
with LOAD, and these alleles are on a single risk haplotype that spans the CR1 gene (Corneveaux et al. 
2010; Lambert et al. 2009; Luo et al. 2014). Identifying the variant within this haplotype that is 
functionally responsible for the genetic association is challenging, yet correct identification will allow a 
functional genetic approach to determine the consequences of the variation in CR1 function, and 
therefore how that variation contributes to LOAD risk. As previously observed, there are at least 60 
missense variants within the risk haplotype (Corneveaux et al. 2010). and it has been suggested that a 
rare missense variant rs4844609 might be responsible for the observed association (Keenan et al. 2012) 
but this observation has not been supported (Van Cauwenberghe et al. 2013).  
 
CR1 is known to contain an intragenic copy number variant (CNV) that alters the number of exons while 
maintaining the reading frame of the protein. The copy number variant is due to variable numbers of a 
tandemly-arranged 18kb repeat unit called a low copy repeat (LCR) (Crehan et al. 2012; Vik and Wong 
1993; Wong et al. 1989; Wong et al. 1983). Each LCR contains eight exons, which together encode a 
C3b/C4b binding domain such that high copy numbers of the LCR result in a longer CR1 molecule with 
more C3b/C4b binding domains (Figure 1). The CR1 CNV has four alleles: CR1-A with two LCRs, CR1-B 
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with three LCRs, CR1-C with one LCR and CR1-D with four LCRs. Each allele can be therefore represented 
by the copy number of the LCR domains. Alleles CR1-A, CR1-B and CR1-C are also known as CR1-F, CR1-S 
and CR1-F’ respectively in the literature, based on their mobilities in protein electrophoresis. Previous 
studies have shown that CR1-A is the most frequent allele in individuals of European origin with a 
frequency of 0.87. CR1-B is the next most frequent, at a frequency of 0.11, with CR1-C and CR1-D at 
frequencies of 0.02 and <0.01 respectively (Moulds et al. 1996). 
 
Although the CR1 LCR CNV affects protein sequence quite dramatically, it is not directly assayed by 
current GWAS. Nevertheless, the association signal observed with SNV haplotypes might be due to a 
CR1 LCR CNV allele if that allele was on that particular SNV haplotype and therefore in linkage 
disequilibrium with the SNV alleles that show association with LOAD. A previous study tested the 
association of the CR1-B allele with LOAD on a cohort of Flemish Belgian patients (n=1039) and controls 
(n=844), and showed that CR1-B carriers showed an increased risk of LOAD (OR 1.32, 95% CI 1.03-1.69, 
p=0.028). They replicated their result on a sample of French patients (n=1393) and controls (n=610) 
(OR=1.33, 1.02-1.74, p=0.039), and showed that this represented the same association signal as that for 
the SNVs rs4844610 and rs1408077 (Brouwers et al. 2012).  
 
Our study aimed firstly to develop a robust assay based on the paralogue ratio test and junction-
fragment PCR for CR1 LCR CNV, in particular for the intragenic duplication allele CR1-B, to facilitate 
further studies. Secondly, we aimed to use our methods to replicate the previous association of CR1 and 
LOAD in a larger cohort. We also investigate the association of CR1-B in a cohort of EOAD to test for a 
stronger risk effect as a result of a more pronounced phenotype. 
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Methods 
 
Samples 
Lymphoblastoid cell lines derived from the 1000 Genomes project samples (Coriell Cell repositories) 
were grown using the standard conditions recommended by the supplier, and DNA isolated using a 
standard phenol-chloroform-based approach. UK samples were purchased as part of Human Random 
Controls plate 1 (HRC-1) from Public Health England. 
 
Human DNA samples were obtained from the Alzheimer’s Research Trust (ART) Collaboration (University 
of Nottingham; University of Manchester; University of Southampton; University of Bristol; Queen’s 
University, Belfast; the Oxford Project to Investigate Memory and Ageing [OPTIMA], Oxford University); 
All case samples were diagnosed as either definite (post mortem confirmed) or probable Alzheimer’s 
disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA), and the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) guidelines. All samples used in this study were 
received with informed consent and were approved by the local Ethics Committee. 
 
The 449 sporadic EOAD samples had an age of disease onset (AAO) ≤ 65 years of age, the 1436 LOAD 
samples had an AAO > 65 years of age and the 1359 controls had an age at death (AAD) > 65 years of 
age. Where AAO was not documented, it was derived assuming 8 years disease duration from age at 
death (Brookmeyer et al. 2002), or age at sampling (AAS) was used with the understanding it would 
approximate to disease onset (Tables 1 and 3). 
 
DNA was extracted from blood or brain tissue using a standard phenol chloroform extraction method. 
DNA quality and quantity was assessed via gel electrophoresis and NanoDrop™ 3300 spectrometer 
respectively. 
 
CR1 copy number estimation from sequence read depth data 
Sequence alignment files in .bam format and corresponding index files in .bai format were downloaded 
from the European Bioinformatics Institute 
(http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/). Using samtools 
software (using the command samtools view -c -F 4 input.bam target_region), the 
number of mapped reads was counted across two intervals (GRCh37 chr1:207,697,239-207,751,921 test 
region, GRCh37 chr1:207,953,949-208,008,574 reference) for each of the samples analysed as part of 
the 1000 Genomes project (CEU individuals for Salt Lake City, Utah, Chinese individuals from Beijing, 
Japanese individuals for Tokyo and Yoruba individuals from Ibadan, Nigeria). A ratio of the reads from 
the copy number variable region:non-copy number variable region was taken as an estimate of CR1 
intragenic copy number. Data are available in dbvar accession nstd159 at ncbi.nlm.nih.gov/dbvar. 
 
CR1 paralogue ratio test 
To determine CR1 intragenic copy number on large numbers, we decided to design three specific assay 
using the paralogue ratio test (PRT), a form of competitive PCR that amplifies a test and reference locus 
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/284711doi: bioRxiv preprint first posted online Mar. 19, 2018; 
 
 
Page 5 of 21 
 
using common primers, and uses the ratio of test and reference amplification products as a measure of 
copy number (Armour et al. 2007; Hollox 2017) (Supplementary Table 1). For each PCR, 5-10ng genomic 
DNA was amplified in a final volume of 10µl, containing 0.5 units Taq DNA polymerase (KAPA), 0.5µl of 
10µM forward primer, 0.5µl of 10µM reverse primer and 1 µl of 10xPCR mix (10xPCR mix = 50mM 
TrisHCl pH8.8@25°C, 12.5mM ammonium sulphate, 1.4mM MgCl2, 125µg/ml BSA (Ambion), 7.5mM 2-
mercaptoethanol and each dNTP (Promega) at a concentration of 200µM). Following PCR amplification 
in an Applied Biosystems Veriti thermal cycler at 95°C for 2 minutes, followed by between 24 and 27 
cycles of 95°C for 20 seconds, 61-63°C for 20 seconds and 72°C for 20 seconds, and finally an elongation 
step at 72°C for 10 minutes. Cycle number and annealing temperatures for each assay are given in 
supplementary table 1. 
 
Between 0.5-1µl of the final product from each assay was combined and added to HiDi Formamide 
(Applied Biosystems) containing 1% MapMarker ROX-labelled size standard. Following denaturation of 
the mixture at 96°C for 3 minutes and snap cooling on ice, the products were run on an Applied 
Biosystems 3130xl capillary sequencer following the manufacturer’s instructions, and areas of the test 
and reference peaks recorded using Genemapper software. For each assay, seven samples of known CR1 
LCR copy number were analysed with each experiment (Supplementary table 2). These samples were 
chosen from the HapMap phase I panel, with copy number inferred from previous array CGH data 
(Conrad et al. 2009) or from preliminary experiments with multiple PRTs. PRT values were normalised 
using the values from the seven positive controls to generate an estimated copy number value. 
 
Calling integer copy number from CR1 PRT data. 
Data from PRT1, PRT2 and PRT3 were concordant across the 1000 Genomes samples analysed so an 
average was taken to represent copy number. For each cohort, a Gaussian mixture model of four or five 
components was fitted to the data using the CNVtools software implemented in the statistical language 
R v.3.2.3, with each component representing a integer copy number class (Barnes et al. 2008). Samples 
were then assigned to each component with a posterior probability, and the component to which they 
were assigned reflected integer copy number call. A statistic Q, which is defined as the ratio of the 
separation of adjacent component means divided by the within-component standard deviation, 
averaged across all components of the mixture model, was calculated for each cohort. This represents 
the degree of clustering of the raw normalised data about integer copy number values (Barnes et al. 
2008). PRT data from the 1000 Genomes samples analysed is available at dbvar accession nstd159 at 
ncbi.nlm.nih.gov/dbvar. 
 
CR1 junction fragment analysis 
PCR products were amplified from 5-10ng genomic DNA in a final volume of 10ul, with 0.5µl of 2.5mM 
of each of dATP, dCTP, dGTP and dTTP, 0.5units Taq DNA polymerase (KAPA Biosciences) and 0.5µl of a 
10µM solution of each PCR primer. The PCR primers were 5’-AATGTGTTTTGATTTCCCAAGATCAG-3’ and 
5’-CTCAACCTCCCAAAGGTGCTA-3’ , with a terminal 3’ locked nucleic acid base (underlined) to increase 
paralogue-specificity (Latorra et al. 2003). A touch-down PCR protocol was used, with an initial 
denaturation step of 95°C for 2 minutes, followed by 20 cycles of 95°C for 30 seconds,  70°C for 30 
seconds decreasing by 0.5°C every cycle to 60°C, and 70°C for 30 seconds. These 20 cycles were then 
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followed by 15 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 70°C for 30 seconds, then a final 
extension step of 70°C for 5 minutes. Products were analysed using standard ethidium bromide stained 
agarose gels and visualisation under ultraviolet light. Specificity of the PCR for CR1-B alleles was 
confirmed on a panel of 40 UK samples from the HRC-1 collection previously typed using PRT. 
 
SNP genotyping and linkage disequilibrium analysis 
Genotyping for the CR1 GWAS index SNP (Lambert et al. 2013), rs6656401, and rs3818361 was carried 
out using KASP assays using standard protocols (LGC, Middlesex).  Pairwise linkage disequilibrium was 
calculated using a cubic exact equation approach implemented in CubeX (Gaunt et al. 2007). 
 
Statistical analysis and sequence alignment 
Clustal Omega was used for sequence alignment provided by the European bioinformatics Institute 
webserver (www.ebi.ac.uk), using default DNA options (Li et al. 2015; Sievers et al. 2011). Case-control 
analysis was performed using logistic regression implemented in the statistical package RStudio v.1.0 
implementing R v3.2.3.   
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Results 
 
Development and validation of PRT assays for CR1 copy number 
 
Our first aim was to develop a simple robust approach to determine the diploid copy number of the 
LCRs within the CR1 gene, which could use small amounts of DNA from large clinical cohorts. The 92% 
similarity between the LCRs within CR1 and part of the CR1L gene allowed the design of three PRT assays 
to independently measure the copy number of LCR (Figure 2a). 
 Analysis of 275 samples from the HapMap collection showed high pairwise concordance (~80%) 
pairwise between the three individual PRT results, allowing an average to be taken of the three PRT 
results for each sample as representative of the copy number of the LCR. For each sample, the copy 
number estimate from the PRT was compared against the copy number estimated from Illumina 
sequencing read depth data. The data showed a high degree of concordance, with data for both 
estimates clustering around integer copy number estimates. In particular, the PRT data shows clear 
distinct clusters, suggesting that it will call copy number accurately (Figure 2b). 
 Because our study was focused on the CR1-B duplication, distinguishing the CR1-A/CR1-B 
heterozygotes (diploid LCR copy number 5) from the CR1-A/CR1-A homozygotes (diploid LCR copy 
number 4) was particularly critical. In order to improve the reliability of distinguishing these genotypes, 
we developed a junction fragment PCR to specifically amplify the LCR1’ repeat. If the LCR1’ repeat was 
generated in the past by an equal crossover between the 98% identical LCR1 and LCR2 sequences, we 
would expect a switch from LCR1-like sequence to LCR2-like sequence within the LCR1’ sequence (Figure 
3). Using a multiple alignment strategy on LCR1, LCR1’ and LCR2 sequences from the human reference 
genome GRCh37, we identified the switch point and confirmed that this is the same switch point found 
in early characterisations of the CR1-B allele (Vik and Wong 1993). Designing PCR primers flanking the 
switch point, with a forward PCR primer specific to the LCR2 sequence and a reverse PCR primer specific 
to the LCR1 will generate an amplification product from CR1-B alleles but not from CR1-A alleles (Figure 
3). 
 
Association analysis of the CR1-B allele with Alzheimer’s disease 
 
 We typed 449 EOAD cases and 184 controls for copy number using our PRT approach (table 1), 
resulting in a dataset that showed clear clustering around integer copy numbers and good separation of 
clusters (Figure 4a). The Q value, a measure of clustering quality of the resulting data, was 5.56, above 
the minimum threshold of 4 previously suggested to be adequate for case-control studies (Barnes et al. 
2008). By calling the individuals with LCR diploid copy numbers of 5 and 6 (CR1-B heterozygotes and 
CR1-B homozygotes respectively), we could infer CR1-B allele dose for each individual. We then used 
logistic regression with sex and ApoE4*4 genotype as covariates to test for the association of CR1-B 
allele with EOAD, assuming an additive effect of the allele. We found no evidence of association 
(p=0.936, table 2). 
 We then typed 1436 LOAD cases and 1175 controls for copy number using our PRT approach 
(table 3). The Q value for this cohort was lower (Q=4.05), and this is reflected in the clustering of values 
(Figure 4b), where there is significant overlap between copy number clusters. To improve calling of copy 
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numbers 4 and 5 (i.e. CR1-B heterozygotes and homozygotes) the junction fragment PCR assay was also 
used on the LOAD cohort. We used logistic regression with sex, age and APOE4*4 genotype as covariates 
to test for the association of CR1-B allele with LOAD, assuming an additive effect of the allele (table 4). 
We confirmed the effect of APOE4*4 allele on increasing LOAD risk (p<2x10-16, odds ratio 3.25, 95% 
confidence intervals for odds ratio 2.78, 3.82), and evidence of association of the CR1-B allele with an 
increased risk of LOAD (p=0.0151, odds ratio 1.21, 95% confidence intervals for odds ratio 1.04, 1.42). 
 
Relationship of CR1-B with flanking SNP alleles 
 
We next attempted to address whether the association we see explains the association at SNPs flanking 
the CR1 gene seen in genomewide association studies. The strength of effect that we observe for the 
CR1-B allele (odds ratio 1.21, 1.04-1.42 95% CI) is consistent with the effect seen for rs6701713-A allele 
(odds ratio 1.16, 1.11-1.22 95% CI, (Naj et al. 2011)) and rs3818361-T allele (odds ratio 1.18, 1.13-1.24 
95% CI, (Hollingworth et al. 2011). We analysed the pairwise linkage disequilibrium between these two 
SNP in a subset of the LOAD cohort (526 cases, 101 controls). We found complete linkage disequilibrium 
(D′=1, r2=1) between rs6701713 and rs3818361, indicating an A-T risk haplotype and a G-C non-risk 
haplotype, similar to previous findings (Mahmoudi et al. 2015). Linkage disequilibrium between both 
SNPs and CR1-B showed LD (D′=0.806, r2=0.576) with the CR1-B allele. The CR1-B allele occurred on the 
A-T risk haplotype (CR1B-rs6701713A- rs3818361T haplotype frequency 0.16) with CR1-B on the non-risk 
haplotype (CR1B-rs6701713G- rs3818361C) infrequent at a frequency of 0.03. This pattern of LD is 
consistent with the CR1-B allele explaining the association observed at the flanking SNP alleles. 
 
If the association of LOAD with the CR1-B allele explains the association at flanking SNP alleles then we 
would expect a stronger association of disease with the CR1 duplication compared to the SNP alleles. 
We analysed a subset of our cohort that had genotypes for rs6701713 and rs3818361 as well as CR1B 
genotype, using the same model used to analyse the full LOAD cohort. Due to limited DNA availability, 
this subset was small (478 cases and 96 controls) and underpowered to detect evidence for an 
association a priori. Nevertheless, the association with CR1-B was stronger (p=0.067, OR 1.52, 95%CI 
0.99-2.44) than with either rs6701713A or rs3818361T (p=0.56, OR=1.13 95%CI 0.76-1.72), and 
incorporating CR1-B rather than rs6701713A or rs3818361T into the logistic regression model provides a 
better fit to the data (Akaike’s information criterion=469.99 vs 473.26). 
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Discussion 
 
In this study we develop a new approach to measuring the copy number variation of LCRs within the CR1 
gene using the paralogue ratio test, together with a junction fragment PCR specific for the CR1-B allele 
that carries three copies of the LCR. We typed a case-control cohort of early-onset Alzheimer’s disease 
and a case-control cohort of late-onset Alzheimer’s disease for copy number of the LCR within the CR1 
gene, inferring the CR1-B genotype. An association study of the CR1B allele with EOAD showed no 
evidence of association, but an association study of the CR1B allele with LOAD provided evidence of 
association of the CR1-B allele with increased LOAD risk, in agreement with previous studies. We also 
show that the CR1-B allele is on the LOAD risk haplotype identified by SNP-based GWAS, and that the 
CR1-B allele shows stronger evidence of association with LOAD than the risk SNP alleles identified by 
GWAS. 
 
One limitation of the PRT approach is that it reports diploid copy number – i.e., the copy number 
summed over both alleles, rather than the true genotype. So, for example, a copy number of 5 could be 
a 3 allele and a 2 allele, or a 4-1 or a 5-0. We assumed that all 5 copy individuals were 3-2, that is CR1-
B/CR1-A and all 6 copy individuals were 3-3 CR1-B/CR1-B not 4-2 CR1-A/CR1-D. This could be an 
incorrect assumption leading to an overestimation of the frequency of the CR1-B allele. Previous work 
has shown, by western blotting of the CR1 protein, that in three out of eight individuals the true 
genotype was CR1-A/CR1-D not CR1-B/CR1-B, suggesting that a significant proportion of 6 copy 
individuals may not be homozygous for CR1-B as we assume (Brouwers et al. 2012). In order to assess 
the validity of our assumption in our population, we estimated the population allele frequencies from 
the diploid copy number data of the EOAD cohort using the R script CNVice, which simultaneously tests 
for any departure of the inferred genotype frequencies from Hardy-Weinberg equilibrium (Zuccherato 
et al. 2017). The relative probability of a genotype given the individual’s copy number was also 
calculated from these results. We found that 4-copy individuals had a 99.2% probability of being CR1-A 
homozygotes, 5-copy individuals had a 100% probability of being CR1-A/CR1-B heterozygotes and 6-
copy individuals had a 100% probability of being CR1-B homozygotes, supporting our assumptions used 
in this study. 
 
The mechanistic basis for the association of the CR1-B allele with LOAD remains unclear. It has been 
suggested that, because of its extra C3b-binding site, the CR1-B protein is more effective at inhibiting 
C3b complement fragments, leading to a reduction in C3b-mediated opsonisation of Ab1-42 fragments 
(Brouwers et al. 2012). However, in brain the CR1-B isoform is expressed at lower levels than CR1-A and 
is probably associated with increased complement activation; indeed, complement system is activated 
by Ab (Hazrati et al. 2012; Mahmoudi et al. 2015; Rogers et al. 1992). Future studies need to focus on 
the functional effect of CR1-B allele in vivo, in combination with structural studies to determine the 
difference in structures between the different CR1 alleles. 
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Figure legends  
 
Figure 1 – Structure of the human CR1 and CR1L region showing the different CNV alleles 
 
The CR1 and CR1L genes are shown, with SNVs that have been reported as associated with late-onset 
Alzheimer’s disease in GWAS shown in green. The duplicated structure of the region is shown, with 
pale/dark orange boxes showing repeated regions that are ~92% similar, and pale/dark blue boxes 
showing regions that are ~99% similar. The genome assembly shows a CR1-B allele, comprised of LCR1, 
LCR2 and LCR1’ which is a fusion of LCR2 and LCR1. The structure of the alternative alleles (CR1-A, CR1-C 
and CR1-D) are shown below, with hatching indicating unclear origin of the LCR. The location of the 
amplification products for the three PRT assays are indicated, with the test amplicons generated from 
the pale orange repeats, and the reference amplicons generated from the dark orange repeat. 
Based in part on the UCSC Genome browser hg38 assembly. 
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Figure 2  - Design and validation of paralogue ratio test to detect CR1 LCR copy number  
 
a) Measuring copy number using the paralogue ratio test. A primer pair is designed so that it 
amplifies from the LCR regions (test) and also from a 92% similar region in CR1L (reference). 
Three independent tests are normalised against seven controls of known copy number, and 
average to obtain an estimate of copy number. 
b) Comparison of CR1 PRT copy number estimate (x axis and histogram) against estimates from 
Illumina sequence read depth (y axis and histogram). Each point represents a different 
individual, points are distinguished by shape and colour indicating the final integer copy number 
call: red cross – 3, green x-cross – 4, blue diamond – 5, cyan triangle - 6. 
 
 
 
  
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/284711doi: bioRxiv preprint first posted online Mar. 19, 2018; 
 
 
Page 13 of 21 
 
 
Figure 3 - Junction fragment PCR for CR1-B allele 
 
A representation of the frequent CR1-B and CR1-A alleles. Paralogue-specific primers (light-blue and 
dark-blue) are used to amplify specifically a breakpoint in LCR1’. Hatched repeats indicates uncertain 
recombinant origin. 
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Figure 4 – Distributions of PRT copy number data. 
 
Histograms showing the distribution of copy number values generated by PRT in a) Early onset cases and 
controls and b) Late onset cases and controls. X axis represents CR1 LCR diploid copy number, with 
Gaussian curves superimposed to indicate the calling of integer copy number, from left to right: black – 
3 copies, green 4 copies, cyan, 5 copies, yellow 6 copies and black (right hand side) >6 copies. 
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Tables 
 
 
Table 1  Characteristics of EOAD cohort and controls  
 
 Cases Controls 
Total N (individuals) 449 184 
Age (median-range) years 57 (37-65) 74 (65-100) 
Sex (males, females) 230,219 92,92 
APOE4*4 -/- 189 136 
APOE4*4 +/- 199 46 
APOE4*4 +/+ 61 2 
CR1-B -/- 293 120 
CR1-B +/- 139 57 
CR1-B +/+ 17 7 
Excluded with missing data 0 0 
N used for association analysis 449 184 
 
 
Table 2  Association of CR1-B allele with EOAD 
 
Parameter B (95% CI) Odds ratio (95% CI) P value 
Intercept 0.293 (-0.0162,0.606) 1.34 (0.984,1.832) 0.0642 
Sex [0 =male , 1=female] 0.0200 (-0.341,0.382) 1.02 (0.711,1.47) 0.914 
APOE4*4 allele 1.24 (0.919,1.59) 3.48 (2.51,4.93) 4.37x10-13 
CR1-B allele  0.0133 (-0.307,0.341) 1.01 (0.735,1.41) 0.936 
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Table 3  Characteristics of LOAD cohort and controls  
 
 Cases Controls 
N (individuals) 1436  1175 
Age (median-range) years 75.1 (43-98) 73.2 (30-100) 
Sex (males, females) 569, 851 532, 639 
APOE4*4 -/- 605 863 
APOE4*4 +/- 670 286 
APOE4*4 +/+ 161 26 
CR1-B -/- 935 839 
CR1-B +/- 422 284 
CR1-B +/+ 79 52 
Excluded with missing age/sex 
data 
256 170 
N used for association analysis 1180 1005 
 
 
 
Table 4   Association of CR1-B allele with LOAD number of cases and controls  
 
Parameter B (95% CI) Odds ratio (95% CI) P value 
Intercept -2.36 (-3.06,-1.67) 0.0944 (0.0467,0.189) 3.48x10-11 
Sex [0 =male , 1=female] 0.149 (-0.0330,0.330) 1.16 (0.967,1.39) 0.109 
Age onset/sampling 0.0242 (0.0153,0.0334) 1.02 (1.02,1.03) 1.48x10-7 
APOE4*4 allele 1.18 (1.02,1.34) 3.25 (2.78,3.82) <2x10-16 
CR1-B allele  0.193 (0.0378, 0.349) 1.21 (1.04,1.42) 0.0151 
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Supplementary Table 1  PRT assays for CR1 LCR copy number 
 
Assay Forward primer 5′3′ Reverse 
primer 5′3′ 
Fluor
escen
t 
label 
Reference 
(CR1L) 
product 
size (bp) 
Test (CR1) 
product 
size (bp) 
Annealing 
temperat
ure (°C) 
Cycle 
number 
PRT1 GAGGAGACCCATAG
TTCTTTACCA 
CATCACCTA
TCACACTGG
TGC 
HEX 108 115 63 24 
PRT2 GCTGTTCCAGGGTC
AGAGTTA 
TTGGTCACA
TGATAGTCC
TGC 
NED 164 187 63 25 
PRT3 CTGTTTGAATAACTA
GGTGGGAAGA 
TTCCCTCCA
GATCTATCT
AGATCTAGA 
FAM 142 149 61 27 
 
Supplementary table 2   Control samples for CR1 paralogue ratio test 
 
Sample ID Population Cohort CR1 LCR copy number 
NA18507 Yoruba from Ibadan, 
Nigeria 
HapMap, 1000 
Genomes 
3 
NA18555 Chinese Han from 
Beijing 
HapMap, 1000 
Genomes 
4 
NA18517 Yoruba from Ibadan, 
Nigeria 
HapMap, 1000 
Genomes 
4 
NA19239 Yoruba from Ibadan, 
Nigeria 
HapMap, 1000 
Genomes 
5 
NA18572 Chinese Han from 
Beijing 
HapMap, 1000 
Genomes 
3 
C0140 UK HRC-1 5 
C0182 UK HRC-1 5 
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